Low-Dose Cannabinoids Prevent Cancer Cachexia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer-induced cachexia and pre-cachexia are ineffective in preventing weight loss and improving survival in cancer patients, as they fail to reverse muscle and fat wasting despite nutritional interventions and anti-inflammatory therapies.
Innovation Solution
Administering low doses of cannabinoids, such as nabilone, before and during chemotherapy, and continuing their use after chemotherapy, to inhibit the onset and progression of pre-cachexia and cachexia in cancer patients, thereby reducing weight loss and improving quality of life.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional nutritional support and anti-inflammatory therapies are administered to cancer patients, then some symptomatic relief may be achieved, but weight loss and muscle wasting continue unabated
Solution Approach 1:
The patent changes the pharmacological parameter by introducing cannabinoids with specific receptor affinity (CB1 and CB2) to alter the metabolic and inflammatory parameters that drive cachexia, thereby preventing weight loss where conventional therapies failed
Solution Approach 2:
Cannabinoids act as intermediary substances that mediate between the harmful catabolic effects of cancer and the body's metabolic processes, blocking the progression of cachexia through receptor-mediated mechanisms
2Reliability
If high doses of cannabinoids are administered to prevent cachexia, then weight loss prevention may improve, but psychoactive side effects and toxicity increase
Solution Approach 1:
The patent optimizes the dosage parameter to low levels (0.1-2.5mg/day) and selects specific cannabinoid compounds with high receptor affinity, achieving effective cachexia prevention while minimizing psychoactive side effects through precise parameter control
Solution Approach 2:
The patent applies partial action by using sub-psychoactive doses of cannabinoids that are sufficient to activate anti-cachexia mechanisms through CB1 and CB2 receptors but insufficient to produce significant psychoactive effects
Data Source
AI summary
The present invention provides a new use for cannabinoids in the prevention of pre-cachexia or cachexia in a patient suffering from cancer, wherein said cannabinoid is administered at low dosage and wherein administration is started prior to chemotherapy and is maintained for at least the duration of the chemotherapy.